BIT225, a Novel Inhibitor of HIV-1 Release from HIV-1 Reservoirs of - PDF document

Nov 06, 2022 •156 likes •302 views

BIT225, a Novel Inhibitor of HIV-1 Release from HIV-1 Reservoirs of the Myeloid Lineage John Wilkinson* 1 , Carolyn Luscombe 1 , Gary Ewart 1 , Stephen Kerr 2 , Nattaya Tanliang 3 , Winai Ratanasuwan 3 , Robert Murphy 4 , and Michelle Miller 1 1

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

AGM 16 October 2009 Key Highlights for 2008/2009 Successful completion of Phase I/IIa

ASX:BIT AGM 16 October 2009 Key Highlights for 2008/2009 Successful completion of Phase I/IIa clinical trial (BIT225-003) of BIT225 in Hep C+ subjects Successful rights issue, raising $0.8 million in March 09 1 BIT225-003:

276 views • 14 slides

BI 201335, a NS3/4A Serine Protease Inhibitor, and BI 207127, a NNI NS5b Polymerase Inhibitor for

BI 201335, a NS3/4A Serine Protease Inhibitor, and BI 207127, a NNI NS5b Polymerase Inhibitor for treatment of chronic HCV infection Wulf Otto Bcher Boehringer Ingelheim Pharma, Biberach, Germany NS3/4A Protease Inhibitor BI 201335 Chemical

629 views • 15 slides

GP IIB/IIIA Inhibitor Use During GP IIB/IIIA Inhibitor Use During Endovascular Intervention

GP IIB/IIIA Inhibitor Use During GP IIB/IIIA Inhibitor Use During Endovascular Intervention Endovascular Intervention Jay S. Yadav M.D. Director, Vascular Intervention Dept of Cardiovascular Medicine The Cleveland Clinic Foundation Name: Jay

1.03k views • 44 slides

HPPD-inhibitor resistance stewardship: The perspective of the HRAC HPPD- inhibitor Working Group

2014 WSSA Vancouver, British Columbia HPPD-inhibitor resistance stewardship: The perspective of the HRAC HPPD- inhibitor Working Group Gordon D. Vail 1 , Roland S. Beffa 2 , William L. Patzoldt 3 , Peter J. Porpiglia 4 and Walter E. Thomas 5

543 views • 16 slides

PhenX Measures: Inhibitors Barbara Konkle and Diane Nugent 4.18 Inhibitors Assays

PhenX Measures: Inhibitors Barbara Konkle and Diane Nugent 4.18 Inhibitors Assays Existing Inhibitor State Evolving Inhibitor State Resolving or Persistent Inhibitor State Laboratory Measures of Inhibitor Impact Factor VIII

275 views • 12 slides

European Inhibitor Network World Haemophilia Day Strasbourg, 19 April 2017 What is the European

European Inhibitor Network World Haemophilia Day Strasbourg, 19 April 2017 What is the European Inhibitor Network? Idea was presented at workshop on the EHC conference in Belgrade 2015 Combat isolation of people with inhibitors (PWI)

526 views • 11 slides

efits of the I inhibitor ivabradine be f inhibitor ivabradine f Y artery d in patients with

S tudy assess I n G the morbidity-mortality S tudy assess I n G the morbidity-mortality N efits of the I be N efits of the I inhibitor ivabradine be f inhibitor ivabradine f Y artery d in patients with coronar Y artery disease isease in

695 views • 20 slides

Umbralisib, A Novel PI3 I3K and Casein Kin inase-1 In Inhibitor, , in in Chronic

Umbralisib, A Novel PI3 I3K and Casein Kin inase-1 In Inhibitor, , in in Chronic Lymphocytic Leukemia and Lymphoma Anthony R Mato, , MD MSCE Memorial Slo loan Kettering Cancer Center NEW DRUGS IN IN HEMATOLOGY BOLOGNA 2018

438 views • 31 slides

What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor

What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor (dabigatran etexilate) Marie Louise S. Christiansen MD, PhD Affiliation: Danish Medicines Agency Declaration of Interests Employment: No interests

557 views • 19 slides

PIT Release Date Functionality 15-May CAB Release

PIT Release Date Functionality 15-May CAB Release Enumeration alignment 24-May Batching Payroll Submission SOAP Bug fixes 19-Jun Agent access Returns Reconciliation

623 views • 26 slides

PIT Release

PIT Release Date Functionality 15-May CAB Release Enumeration alignment 24-May Batching Payroll Submission SOAP Bug fixes 19-June

506 views • 21 slides

AT-007, a Novel CNS Penetrant Aldose Reductase Inhibitor Prevents the Metabolic and Tissue

AT-007, a Novel CNS Penetrant Aldose Reductase Inhibitor Prevents the Metabolic and Tissue Specific Abnormalities of Galactosemia in a GALT Deficient Rat Model of Disease Riccardo Perfetti, MD, PhD Chief Medical Officer, Applied Therapeutics

312 views • 13 slides

Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with

Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with Activity Against all HCV Genotypes Richard Colonno, Ningwu Huang, Margaret Bencsik, Eric Peng, Anja Huq, Qi Huang, Min Zhong and Leping Li Presidio

783 views • 15 slides

BLU-782 A highly selective ALK2 inhibitor, designed specifically to target the cause of

BLU-782 A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva Andrew Garner, Ph.D. ASBMR ANNUAL MEETING SEPTEMBER 30, 2018 Disclosures I am an employee and stockholder of

633 views • 16 slides

OVERALL SURVIVAL IN KATE2 (NCT02924883): A PHASE 2 STUDY OF PD-L1 INHIBITOR ATEZOLIZUMAB +

OVERALL SURVIVAL IN KATE2 (NCT02924883): A PHASE 2 STUDY OF PD-L1 INHIBITOR ATEZOLIZUMAB + TRASTUZUMAB EMTANSINE (T-DM1) VS PLACEBO + T-DM1 IN PREVIOUSLY TREATED HER2-POSITIVE ADVANCED BREAST CANCER Leisha A. Emens , 1 Francisco Esteva, 2 Mark

747 views • 17 slides

MoveDMD: Phase 1/2 Trial of Edasalonexent, an NF- B Inhibitor, in 4 to 7-Year Old Patients with

MoveDMD: Phase 1/2 Trial of Edasalonexent, an NF- B Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy Richard Finkel, MD 1, ; Krista Vandenborne, PT, PhD. 2 , H Lee Sweeney, PhD. 2 , Erika Finanger, MD 3 , Gihan Tennekoon,

610 views • 22 slides

Awa wareness reness - A HIV V Cas ase NRP EEEjr01A Leung Fee Ming Shannon & Toh Yee

Ga Gami mifi fica catio tion n for Cultiv ltivating ating Soci cial al Awa wareness reness - A HIV V Cas ase NRP EEEjr01A Leung Fee Ming Shannon & Toh Yee Shuen, Kaela Presentation Outline 1. Introduction a. Gamification b.

635 views • 24 slides

WHO Update Irena Prat and Jose Hansen World Health Organization Vancouver, 14-16 March 2017

WHO Update Irena Prat and Jose Hansen World Health Organization Vancouver, 14-16 March 2017 What's new ? Prequalification of IVDs New guidance documents Post-market surveillance Inspections Regulatory strengthening 2

364 views • 13 slides

Donor Characterisation and Identification of Infection Transmission Risks (Beyond S. aureus )

Donor Characterisation and Identification of Infection Transmission Risks (Beyond S. aureus ) Ins.Ushiro-Lumb@nhsbt.nhs.uk Lead Clinical Microbiologist for Organ Donation and Transplantation Take home messages: To reflect on Rationale

908 views • 25 slides

Cultural Competence & Field Instruction: working with US-Mexico transnational populations in

Cultural Competence & Field Instruction: working with US-Mexico transnational populations in Southern California: Substance Use and increased risk for poor health outcomes, specifically HIV. Mara Luisa Ziga, Ph.D. Associate Professor

1.06k views • 44 slides

Heather Lorenz, MSOH, CIH, CSP, CMLSO Director, EHRS Environmental Health and Radiation Safety

Heather Lorenz, MSOH, CIH, CSP, CMLSO Director, EHRS Environmental Health and Radiation Safety Department Health Science Campus, Main Campus, Scott Park, Lake Erie Center and the UT Medical Center and associated clinics. Responsible

1.06k views • 48 slides

Dynamics of the HIV Treatment Cascade in the United States To download today s presentation

PHSSR Research-In-Progress Series: Quality, Cost and Value of Public Health Services Wednesday, June 3, 2015 12:00 - 1:00 pm ET Go With the Flow: Understanding the Temporal Dynamics of the HIV Treatment Cascade in the United States To

481 views • 22 slides

2/4/14 Debate: Haploidentical (haplo) versus Umbilical Cord Blood (UCB) Transplant Ephraim

2/4/14 Debate: Haploidentical (haplo) versus Umbilical Cord Blood (UCB) Transplant Ephraim Joseph Fuchs, MD, MBA Professor of Oncology and Immunology Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, MD Objectives

357 views • 9 slides

Strategies to improve long-term outcomes after kidney transplantation Miha Arnol 5 th Congres of

Strategies to improve long-term outcomes after kidney transplantation Miha Arnol 5 th Congres of Nephrology in BIH, Tuzla, October 18, 2019 Kidney transplant medicine A story of success A story of barriers A story of how modern

692 views • 54 slides